Literature DB >> 22333878

XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells.

S Rafiq, C Cheney, X Mo, D Jarjoura, N Muthusamy, J C Byrd.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22333878      PMCID： PMC3676652          DOI： 10.1038/leu.2012.40

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases.

Authors:  P Chevallier; N Robillard; G Houille; S Ayari; T Guillaume; J Delaunay; J-L Harousseau; H Avet-Loiseau; M Mohty; R Garand
Journal:  Leukemia       Date:  2008-10-30       Impact factor: 11.528

2.  CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.

Authors:  Farrukh T Awan; Rosa Lapalombella; Rossana Trotta; Jonathan P Butchar; Bo Yu; Don M Benson; Julie M Roda; Carolyn Cheney; Xiaokui Mo; Amy Lehman; Jeffrey Jones; Joseph Flynn; David Jarjoura; John R Desjarlais; Susheela Tridandapani; Michael A Caligiuri; Natarajan Muthusamy; John C Byrd
Journal:  Blood       Date:  2009-12-02       Impact factor: 22.113

3.  A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.

Authors:  Elizabeth Ward; Nanette Mittereder; Ellen Kuta; Gary P Sims; Michael A Bowen; William Dall'Acqua; Thomas Tedder; Peter Kiener; Anthony J Coyle; Herren Wu; Bahija Jallal; Ronald Herbst
Journal:  Br J Haematol       Date:  2011-09-09       Impact factor: 6.998

4.  B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody.

Authors:  Ronald Herbst; Yue Wang; Sandra Gallagher; Nanette Mittereder; Ellen Kuta; Melissa Damschroder; Rob Woods; Daniel C Rowe; Li Cheng; Kim Cook; Krista Evans; Gary P Sims; David S Pfarr; Michael A Bowen; William Dall'Acqua; William Dall'Aqua; Mark Shlomchik; Thomas F Tedder; Peter Kiener; Bahija Jallal; Herren Wu; Anthony J Coyle
Journal:  J Pharmacol Exp Ther       Date:  2010-07-06       Impact factor: 4.030

5.  Trends in leukemia incidence and survival in the United States (1973-1998).

Authors:  Yang Xie; Stella M Davies; Ying Xiang; Leslie L Robison; Julie A Ross
Journal:  Cancer       Date:  2003-05-01       Impact factor: 6.860

6.  Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.

Authors:  Deborah A Thomas; Susan O'Brien; Stefan Faderl; Guillermo Garcia-Manero; Alessandra Ferrajoli; William Wierda; Farhad Ravandi; Srdan Verstovsek; Jeffrey L Jorgensen; Carlos Bueso-Ramos; Michael Andreeff; Sherry Pierce; Rebecca Garris; Michael J Keating; Jorge Cortes; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2010-07-26       Impact factor: 44.544

7.  Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.

Authors:  Holly M Horton; Matthew J Bernett; Erik Pong; Matthias Peipp; Sher Karki; Seung Y Chu; John O Richards; Igor Vostiar; Patrick F Joyce; Roland Repp; John R Desjarlais; Eugene A Zhukovsky
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

8.  Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.

Authors:  Ralf Bargou; Eugen Leo; Gerhard Zugmaier; Matthias Klinger; Mariele Goebeler; Stefan Knop; Richard Noppeney; Andreas Viardot; Georg Hess; Martin Schuler; Hermann Einsele; Christian Brandl; Andreas Wolf; Petra Kirchinger; Petra Klappers; Margit Schmidt; Gert Riethmüller; Carsten Reinhardt; Patrick A Baeuerle; Peter Kufer
Journal:  Science       Date:  2008-08-15       Impact factor: 47.728

9.  A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.

Authors:  Anne L Angiolillo; Alice L Yu; Gregory Reaman; Ashish M Ingle; Rita Secola; Peter C Adamson
Journal:  Pediatr Blood Cancer       Date:  2009-12       Impact factor: 3.167

10.  Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia.

Authors:  Alexander Claviez; Cornelia Eckert; Karl Seeger; André Schrauder; Martin Schrappe; Günter Henze; Arend von Stackelberg
Journal:  Haematologica       Date:  2006-02       Impact factor: 9.941
View more
  5 in total

Review 1.  CD19 as an attractive target for antibody-based therapy.

Authors:  Ohad Hammer
Journal:  MAbs       Date:  2012-07-23       Impact factor: 5.857

2.  Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.

Authors:  Sarwish Rafiq; Anthony Siadak; Jonathan P Butchar; Carolyn Cheney; Gerard Lozanski; Naduparambil K Jacob; Rosa Lapalombella; Jackie McGourty; Meghan Moledor; Richard Lowe; Ben Setter; Jeffrey Jones; Joseph M Flynn; Leslie Andritsos; Steven Devine; Xiaokui Mo; David Jarjoura; Susheela Tridandapani; Paul Algate; John C Byrd; Natarajan Muthusamy
Journal:  MAbs       Date:  2013-06-07       Impact factor: 5.857

3.  Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands.

Authors:  Wing Keung Chan; May Kung Sutherland; Ying Li; Jonathan Zalevsky; Sarah Schell; Wing Leung
Journal:  Clin Cancer Res       Date:  2012-09-26       Impact factor: 12.531

Review 4.  Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.

Authors:  Pier Luigi Zinzani; Giorgio Minotti
Journal:  J Cancer Res Clin Oncol       Date:  2021-11-06       Impact factor: 4.553

5.  A novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery.

Authors:  Yicheng Mao; Jiang Wang; Yuan Zhao; Yun Wu; Kwang Joo Kwak; Ching-Shih Chen; John C Byrd; Robert J Lee; Mitch A Phelps; L James Lee; Natarajan Muthusamy
Journal:  Nanomedicine       Date:  2013-08-20       Impact factor: 5.307
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.